$-0.35 EPS Expected for ADMA Biologics, Inc. (ADMA)

July 14, 2018 - By Carolyn Hewitt

ADMA Biologics, Inc. (NASDAQ:ADMA) LogoInvestors sentiment decreased to 2.86 in Q1 2018. Its down 0.14, from 3 in 2017Q4. It dived, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported.
Barclays Public Limited Company has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Morgens Waterfall Vintiadis owns 300,000 shares or 1.05% of their US portfolio. Spark Investment Mngmt Ltd Limited Liability Company invested 0.01% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Northern Tru reported 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Element Cap Management Limited Liability Corporation, New York-based fund reported 25,663 shares. Blackrock holds 0% or 40,536 shares in its portfolio. Aisling Cap Ltd Limited Liability Company reported 2.96% stake. Millennium Limited Liability Corporation has 273,621 shares for 0% of their portfolio. Broadfin Capital Limited Liability Com reported 720,529 shares. Vanguard Gp has 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 886,987 shares. Prelude Cap Limited Liability, New York-based fund reported 57,300 shares. 23,568 are held by Bluecrest Cap Mngmt Ltd. State Bank Of Mellon has 19,037 shares for 0% of their portfolio. 4,000 are owned by Royal Savings Bank Of Canada. Consonance Cap Lp holds 1.4% or 3.33 million shares.

Since June 8, 2018, it had 5 buys, and 0 insider sales for $744,504 activity. The insider Guiheen Lawrence P. bought 20,000 shares worth $95,600. RICHMAN ERIC I had bought 5,230 shares worth $24,999 on Friday, June 8. LENZ BRIAN bought $23,900 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) on Friday, June 8. Grossman Adam S had bought 73,222 shares worth $350,001 on Friday, June 8.

Analysts expect ADMA Biologics, Inc. (NASDAQ:ADMA) to report $-0.35 EPS on August, 10.They anticipate $0.20 EPS change or 36.36 % from last quarter’s $-0.55 EPS. After having $-0.35 EPS previously, ADMA Biologics, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.09% or $0.14 during the last trading session, reaching $4.67. About 457,054 shares traded or 99.57% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since July 14, 2017 and is uptrending. It has outperformed by 37.29% the S&P500.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $210.59 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Seekingalpha.com which released: “ADMA Biologics: The Right Way To Fix Manufacturing” on June 14, 2018, also Nasdaq.com with their article: “ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes” published on June 25, 2018, Seekingalpha.com published: “Rounds Report: Versartis Rallied Due To Strong Turnaround Progress” on June 15, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Benzinga.com and their article: “30 Stocks Moving In Friday’s Mid-Day Session” published on July 13, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: July 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.